-
Posted by
Two Blokes Jun 26 -
Filed in
Stock
-
4 views
– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings – – Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker – – Encouraging Phase 2 observations in Duchenne define the dose and inform design for Phase 3 – – Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo.
